Inspiremd Inc (NSPR) Stock Price, Quote & News

Company Profile

InspireMD, Inc., a medical device company, focuses on the development and commercialization of products for the treatment of carotid artery disease and other vascular conditions in the United States, Germany, Italy, Russia, Poland, and internationally. It offers MicroNet, a biocompatible polymer mesh material for medical implants, as well as for treating plaque prolapse and embolization; CGuard carotid embolic prevention system (EPS) for use in carotid artery applications; CGuard Prime Carotid S...

Industry: Medical Devices

Sector: Healthcare

Phone: 888 776 6804

Website: www.inspiremd.com

Address:

6303 Waterford District Drive, Suite 215, Miami, United States

OGTDeepWaters May. 13 at 11:21 AM

$NSPR Well now Paul Stuka bought more as well, very positive sign. https://www.sec.gov/Archives/edgar/data/1433607/000149315226022564/xslF345X06/ownership.xml

0 · Reply

LoyalShark May. 11 at 5:24 PM

$NSPR The declining tops line is at $1.84 --- need that to change the trend of the channel.

0 · Reply

LoyalShark May. 11 at 5:08 PM

$NSPR Looking for a test of $1.53 then $1.97 to lock in the reversal off the bottom.

0 · Reply

Onmywayup2021 May. 11 at 3:26 PM

$NSPR get ready boys and girls!!! The chart is charting nicely for the next few days🤗🤗🤗. Not financial advice of course. With bad news of BSX'S recall of several types of pacemakers, I wonder what this will do for NSPR 🤔😎. Whatever the case I'm optimistic for the short term. We still have a ways to go

0 · Reply

DonutHole May. 11 at 2:03 PM

$NSPR Added to the list after the insider buying. https://www.realcreativeagency.com/best-penny-stocks-to-watch/#NSPR

0 · Reply

OGTDeepWaters May. 11 at 9:21 AM

$NSPR Medtronic or Boston - both need it, one loses market share after blowing out 1.26 b's, the other needs it to become a more complete solution, either way NSPR long term holders win. Perhaps 4th Q this year so as not to have to pay more. Chump change for those guys.

0 · Reply

arcuy May. 11 at 8:11 AM

$NSPR nice one Gary! 👏

0 · Reply

Capital_Gains_X May. 8 at 11:07 PM

$NSPR this feels like a good time to start chasing the bottom here.

1 · Reply

Threeways May. 8 at 9:35 PM

$NSPR 180,000+ shares bought by insiders. Maybe this will run next week now

3 · Reply

BigBalla01 May. 8 at 9:29 PM

$NSPR form 4 filed. 90,000 shares bought at 1.18

1 · Reply

InspireMD to Participate in Upcoming Bank of America Securities 2026 Global Healthcare Conference

2026-05-05T11:00:54.000Z - 8 days ago

InspireMD price target lowered to $3 from $4 at Piper Sandler

2026-05-04T20:44:33.000Z - 8 days ago

InspireMD reports Q1 EPS (16c), consensus (18c)

May 4, 2026, 4:30 PM EDT - 8 days ago

InspireMD Earnings Call Transcript: Q1 2026

May 4, 2026, 4:05 PM EDT - 8 days ago

InspireMD Reports First Quarter 2026 Financial Results

2026-05-04T13:51:18.000Z - 8 days ago

InspireMD price target lowered to $4 from $5 at Lake Street

2026-05-04T13:50:39.000Z - 8 days ago

InspireMD withdrawing prior FY26 revenue guidance

2026-05-04T12:51:38.000Z - 8 days ago

InspireMD initiates voluntary U.S. recall of CGuard Prime 135 cm system

2026-05-01T20:11:00.000Z - 11 days ago

InspireMD announces FDA approval of IDE application for CGUARDIANS III study

May 1, 2026, 4:05 PM EDT - 11 days ago

InspireMD Initiates Voluntary U.S. Recall of CGuard® Prime 135 cm Carotid Stent Delivery System

May 1, 2026, 4:05 PM EDT - 11 days ago

InspireMD Announces FDA Approval of Investigational Device Exemption Application for CGUARDIANS III Pivotal Study of the SwitchGuard Neuro Protection System

Apr 27, 2026, 4:05 PM EDT - 15 days ago

InspireMD to Announce First Quarter 2026 Financial Results

Apr 14, 2026, 12:45 PM EDT - 4 weeks ago

InspireMD Transcript: 25th Annual Needham Virtual Healthcare Conference

Mar 31, 2026, 4:05 PM EDT - 6 weeks ago

InspireMD to Participate in Upcoming 25th Annual Needham Virtual Healthcare Conference

Mar 18, 2026, 8:30 AM EDT - 7 weeks ago

InspireMD Earnings Call Transcript: Q4 2025

2026-03-18T11:11:13.000Z - 2 months ago

InspireMD reports Q4 EPS (14c), consensus (19c)

2026-03-18T11:10:33.000Z - 2 months ago

InspireMD sees FY26 revenue $13M-$15M, consensus $14.55M

Mar 18, 2026, 7:00 AM EDT - 2 months ago

InspireMD Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 9, 2026, 9:00 AM EDT - 2 months ago

InspireMD to Announce Fourth Quarter and Full Year 2025 Financial Results

2026-02-12T15:11:44.000Z - 3 months ago

InspireMD participates in a conference call with Lake Street

2026-02-02T12:45:07.000Z - 3 months ago

InspireMD initiated with a Buy at Maxim

2026-01-20T14:05:16.000Z - 4 months ago

InspireMD reports inducement grants under Nasdaq listing rule

Jan 20, 2026, 9:00 AM EST - 4 months ago

InspireMD Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-01-12T14:20:11.000Z - 4 months ago

InspireMD announces publication of C-GUARDIANS trial

Jan 12, 2026, 9:00 AM EST - 4 months ago

InspireMD Announces Publication of the C-GUARDIANS Pivotal Trial Manuscript in the Journal of the American College of Cardiology (JACC)

Dec 3, 2025, 12:30 PM EST - 5 months ago

InspireMD Transcript: Piper Sandler 37th Annual Healthcare Conference

2025-11-24T12:45:11.000Z - 6 months ago

InspireMD announces publication of CREST-2 data in NEJM

Nov 24, 2025, 7:30 AM EST - 6 months ago

Landmark CREST-2 Study Published in the New England Journal of Medicine Highlights the Benefits of Carotid Artery Stenting

2025-11-21T14:05:27.000Z - 6 months ago

InspireMD reports inducement grants under Nasdaq listing rule

Nov 19, 2025, 4:42 PM EST - 6 months ago

InspireMD to Participate in Upcoming Piper Sandler 37th Annual Healthcare Conference

Nov 4, 2025, 8:30 AM EST - 6 months ago

InspireMD Earnings Call Transcript: Q3 2025

2025-11-04T12:15:34.000Z - 6 months ago

InspireMD reports Q3 EPS (17c) vs (16c) last year

Nov 4, 2025, 7:00 AM EST - 6 months ago

InspireMD Reports Third Quarter 2025 Financial Results

2025-11-03T12:42:01.000Z - 6 months ago

InspireMD names Peter Soukas as Chief Medical Officer

Nov 3, 2025, 7:30 AM EST - 6 months ago

InspireMD Names Peter A. Soukas, M.D.

Oct 21, 2025, 4:05 PM EDT - 7 months ago

InspireMD to Announce Third Quarter 2025 Financial Results

2025-10-08T12:10:11.000Z - 7 months ago

InspireMD reports inducement grants under Nasdaq listing rule

Sep 17, 2025, 8:00 AM EDT - 8 months ago

InspireMD Announces the Appointment of Dan Dearen to its Board of Directors

Sep 10, 2025, 10:00 AM EDT - 8 months ago

InspireMD Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 27, 2025, 9:00 AM EDT - 9 months ago

InspireMD to Present at Upcoming H.C. Wainwright 27th Annual Global Investment Conference

Aug 5, 2025, 8:30 AM EDT - 10 months ago

InspireMD Earnings Call Transcript: Q2 2025

Aug 5, 2025, 8:00 AM EDT - 10 months ago

InspireMD Reports Second Quarter 2025 Financial Results

Jul 31, 2025, 8:31 AM EDT - 10 months ago

InspireMD Announces the Appointment of Raymond W. Cohen to its Board of Directors

Jul 31, 2025, 8:30 AM EDT - 10 months ago

InspireMD Announces Combined Financings of $58 Million

Jul 22, 2025, 7:00 AM EDT - 10 months ago

InspireMD to Announce Second Quarter 2025 Financial Results

Jul 9, 2025, 7:00 AM EDT - 11 months ago

InspireMD Announces U.S. Commercial Launch of CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 24, 2025, 4:05 PM EDT - 11 months ago

InspireMD Announces FDA Approval for CGuard® Prime Carotid Stent System for the Prevention of Stroke

Jun 13, 2025, 9:00 AM EDT - 11 months ago

InspireMD Announces CE Mark Approval for CGuard® Prime Embolic Prevention System (EPS) Under European MDR for the Prevention of Stroke

Jun 3, 2025, 4:05 PM EDT - 1 year ago

InspireMD Announces Appointment of Michael Lawless as Chief Financial Officer

May 14, 2025, 1:15 PM EDT - 1 year ago

InspireMD Transcript: Bank of America 2025 Healthcare Conference

May 9, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q1 2025

May 9, 2025, 7:00 AM EDT - 1 year ago

InspireMD Reports First Quarter 2025 Financial Results

Apr 30, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Present at Upcoming Bank of America 2025 Healthcare Conference

Apr 25, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Announce First Quarter 2025 Financial Results

Apr 9, 2025, 8:00 AM EDT - 1 year ago

InspireMD Transcript: 24th Annual Needham Virtual Healthcare Conference

Mar 26, 2025, 9:00 AM EDT - 1 year ago

InspireMD to Present at Upcoming 24th Annual Needham Virtual Healthcare Conference

Mar 12, 2025, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q4 2024

Mar 12, 2025, 7:00 AM EDT - 1 year ago

InspireMD Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 8:00 AM EST - 1 year ago

InspireMD to Announce Fourth Quarter and Full Year 2024 Financial Results

Feb 13, 2025, 7:00 AM EST - 1 year ago

InspireMD and NAMSA to Partner on CGUARDIANS II Pivotal Clinical Trial of the CGuard Prime™ 80 cm Carotid Stent System for Use in TCAR procedures

Dec 9, 2024, 7:00 AM EST - 1 year ago

InspireMD Announces First Patient Enrolled in the CGUARDIANS II Pivotal Study of the CGuard Prime Carotid Stent System in Transcarotid Artery Revascularization Procedures (TCAR)

Nov 25, 2024, 4:05 PM EST - 1 year ago

InspireMD Announces Appointment of Accomplished Medical Technology Executive Scott R. Ward to its Board of Directors

Nov 12, 2024, 8:30 AM EST - 1 year ago

InspireMD Earnings Call Transcript: Q3 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Establishment of Global Headquarters in Miami, Florida to Support Anticipated U.S. Launch and Commercialization of the CGuard Prime Carotid Stent System

Oct 7, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Approval of Investigational Device Exemption (IDE) Application for CGUARDIANS II Pivotal Study of the CGuard Prime 80cm Carotid Stent System

Sep 16, 2024, 7:00 AM EDT - 1 year ago

InspireMD Announces Submission of Premarket Approval Application to FDA Seeking U.S. Regulatory Approval of the CGuard™ Prime Carotid Stent System

Aug 6, 2024, 8:30 AM EDT - 1 year ago

InspireMD Earnings Call Transcript: Q2 2024

Aug 6, 2024, 8:09 AM EDT - 1 year ago

InspireMD Reports Second Quarter 2024 Financial Results and Provides Business Update

Aug 5, 2024, 7:00 AM EDT - 1 year ago

InspireMD Congratulates CREST-2 Investigators on Completion of Trial Enrollment

Jul 30, 2024, 7:00 AM EDT - 1 year ago

InspireMD to Report Second Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, August 6th

May 28, 2024, 8:53 AM EDT - 2 years ago

InspireMD Announces Presentation of Positive One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial of CGuard at LINC 2024

May 14, 2024, 8:30 AM EDT - 2 years ago

InspireMD Earnings Call Transcript: Q1 2024

May 14, 2024, 7:00 AM EDT - 2 years ago

InspireMD Reports First Quarter 2024 Financial Results and Provides Business Update

May 7, 2024, 7:00 AM EDT - 2 years ago

InspireMD to Report First Quarter 2024 Financial Results and Provide Corporate Business Update on Tuesday, May 14th

Apr 10, 2024, 8:00 AM EDT - 2 years ago

InspireMD Transcript: 23rd Annual Needham Virtual Healthcare Conference

Apr 3, 2024, 8:59 AM EDT - 2 years ago

InspireMD to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 26, 2024, 7:00 AM EDT - 2 years ago

InspireMD Announces Abstract of One-Year Follow-Up Results from the C-GUARDIANS U.S. Investigational Device Exemption (IDE) Clinical Trial Accepted for Presentation at LINC 2024

Mar 6, 2024, 8:30 AM EST - 2 years ago

InspireMD Earnings Call Transcript: Q4 2023

Mar 6, 2024, 7:00 AM EST - 2 years ago

InspireMD Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update

Feb 28, 2024, 7:00 AM EST - 2 years ago

InspireMD to Report Fourth Quarter and Full-Year 2023 Financial Results and Provide Corporate Business Update on Wednesday, March 6th

Feb 12, 2024, 7:00 AM EST - 2 years ago

InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System

Jan 31, 2024, 7:00 AM EST - 2 years ago

InspireMD Receives CE Mark Recertification Under EU's New Medical Device Regulation (MDR) Regulatory Framework

OGTDeepWaters May. 13 at 11:21 AM

$NSPR Well now Paul Stuka bought more as well, very positive sign. https://www.sec.gov/Archives/edgar/data/1433607/000149315226022564/xslF345X06/ownership.xml

0 · Reply

LoyalShark May. 11 at 5:24 PM

$NSPR The declining tops line is at $1.84 --- need that to change the trend of the channel.

0 · Reply

LoyalShark May. 11 at 5:08 PM

$NSPR Looking for a test of $1.53 then $1.97 to lock in the reversal off the bottom.

0 · Reply

Onmywayup2021 May. 11 at 3:26 PM

0 · Reply

DonutHole May. 11 at 2:03 PM

$NSPR Added to the list after the insider buying. https://www.realcreativeagency.com/best-penny-stocks-to-watch/#NSPR

0 · Reply

OGTDeepWaters May. 11 at 9:21 AM

0 · Reply

arcuy May. 11 at 8:11 AM

$NSPR nice one Gary! 👏

0 · Reply

Capital_Gains_X May. 8 at 11:07 PM

$NSPR this feels like a good time to start chasing the bottom here.

1 · Reply

Threeways May. 8 at 9:35 PM

$NSPR 180,000+ shares bought by insiders. Maybe this will run next week now

3 · Reply

BigBalla01 May. 8 at 9:29 PM

$NSPR form 4 filed. 90,000 shares bought at 1.18

1 · Reply

OGTDeepWaters May. 8 at 4:51 PM

$NSPR Yes it sucks now being down here, but second half is extremely bullish and if management has a brain they wont sell any shares to raise until back above 2 and only dish out small amounts to push this into late 2027, then it gets really interesting. But who knows many companies are run by morons, but this could just be the IMMU moment so to speak. I did extremely well on this, ahh memories.

0 · Reply

TheLastKings May. 8 at 2:02 AM

$NSPR

0 · Reply

Threeways May. 7 at 3:38 PM

$NSPR I’m curious how this affects the K warrants from the PIPE financing. I assume this pushes them back and hopefully helps the stock as it won’t hit around the same time as TCAR approval

1 · Reply

OGTDeepWaters May. 6 at 10:51 PM

$NSPR In Ray we trust.

0 · Reply

fever69 May. 6 at 4:50 PM

$NSPR

0 · Reply

Onmywayup2021 May. 6 at 11:40 AM

$NSPR I might wait another day or two and buy a couple of shares. The chart doesn't look great, but after that last report, I'm certain people are watching the stock. Who knows? Maybe BSX or MDT will offer a buyout 🤔. The real question is, will NSPR accept the offer or become a fierce competitor?

1 · Reply

HOBOWITHASHOTGUN May. 5 at 6:49 PM

$NSPR Looks like I'm going to be here awhile. Better get settled in...

0 · Reply

RedDogSailor May. 5 at 6:39 PM

$NSPR This is stupid cheap now. Lots of cash, momentum, without peer and wide open runway.

1 · Reply

OGTDeepWaters May. 5 at 5:01 PM

$NSPR Well I have been buying here above 1, we'll see, in a year this can look vastly different.

0 · Reply

JBinLB May. 5 at 2:46 PM

$NSPR sad to see it’s still a half pint of dookie noodle soup

0 · Reply

GiveHerTheDD May. 5 at 2:35 PM

$NSPR May 2026 investor presentation posted! They have all of the catalysts now laid out for us. Big things coming. https://investors.inspiremd.com/static-files/45f09f69-6761-43e6-bfeb-84fe387fc91e

0 · Reply

LoyalShark May. 5 at 12:35 PM

$NSPR Curious why the 'old delivery device that is used throughout the rest of the world in 70,000 cases was not already through the approval process given it was used in the CGuard trials in the US ?? Anyone know?

1 · Reply

Market Cap	58.55M
Revenue (ttm)	8.98M
Net Income (ttm)	-48.79M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-543.32%
Debt to Equity Ratio	0.00

Volume	161,600
Avg Vol	303,416
Day's Range	N/A - N/A
Shares Out	46.84M
Stochastic %K	67%
Beta	0.82
Analysts	Strong Sell
Price Target	$4.33